Group 1 - The Hong Kong stock market opened slightly higher, with the Hang Seng Index at 26,754.93 points, up 58.52 points, a gain of 0.22% [1] - The Hang Seng Tech Index reported 5,939.69 points, increasing by 15.30 points, a rise of 0.26% [3] Group 2 - Heisai-W (HK02525) announced a net revenue of RMB 795 million for Q3, a year-on-year increase of 47.5%, and a net profit of RMB 256 million, turning from loss to profit. The full-year net profit guidance was raised to between RMB 350 million and RMB 450 million, with Q4 net revenue expected to be between RMB 1 billion and RMB 1.2 billion, a year-on-year growth of approximately 39% to 67%. However, Heisai's stock fell over 10% in early trading [4] - China General Nuclear Power New Energy (HK01811) reported a cumulative power generation of 15,753.4 GWh for the first 10 months, a decrease of 3.5% year-on-year [6] - Dongyao Pharmaceutical-B (HK01875) announced a revenue of RMB 622 million for the nine months ending September 30, 2025, with a net loss attributable to equity holders of RMB 3.371 million [6] Group 3 - The innovative drug sector saw collective gains in early trading, with BeiGene rising over 4%, Kailaiying up over 1.8%, and Zhaoyan New Drug, WuXi AppTec, and WuXi Biologics each increasing by over 1% [8] - In other sectors, tech stocks showed mixed performance, with Xiaomi up over 2%, Tencent and NetEase rising over 1%, while Alibaba and Baidu fell over 2%. Real estate stocks were active, with Shimao Group increasing over 3%, and some automotive stocks opened higher, with XPeng Motors up over 2% [9] Group 4 - According to China Merchants Securities, the recent volatility in the Hong Kong stock market is partly due to investors taking profits, but this expectation gap creates investment opportunities. With a turning point in the U.S. government shutdown and an upward revision of external liquidity expectations, the market may open new upward space after consolidation [10]
港股速报｜港股小幅高开 创新药板块早盘走强